INTENDED AUDIENCE
This activity is intended for healthcare providers who actively treat/manage patients with pulmonary hypertension due to interstitial lung disease (PH-ILD).
EDUCATIONAL OBJECTIVES
After attending this activity, the participant will demonstrate the ability to:
  1. Identify early signs, symptoms, and assessments to facilitate a timely and accurate diagnosis of pulmonary hypertension among patients with interstitial lung disease (PH-ILD)
  2. Recognize the impact of screening for mild/borderline PH among patients with ILD to facilitate an early intervention
  3. Evaluate the safety and efficacy of approved and emerging therapy approaches for PH-ILD to enable improved outcomes
  4. Discuss strategies to implement recent progress and design individualized treatment plans to improve the quality of life of diverse patients with PH-ILD
AGENDA
6:00AM

Registration and Breakfast
6:15AM

Introduction and Burden of PH Associated with ILD
6:20AM

Early Recognition of PH Among Patients with ILD
6:25AM

Facilitating an Accurate Diagnosis and the Role of Mild PH
6:35AM

Key Evidence in the Treatment of PH-ILD
6:45AM

Case Studies to Incorporate Evidence into Practice
7:15AM

Updates in Diagnosis, Treatment and Management
7:25AM

Conclusion and Questions
FACULTY

Steven Nathan, MD

Medical Director, Advanced Lung Disease
and Transplant Program
Inova Fairfax Hospital

Jean Elwing, MD

Professor of Medicine
Director, Pulmonary Hypertension Program
University of Cincinnati

Ioana Preston, MD

Associate Professor of Medicine
Tufts University School of Medicine
Director, Pulmonary Hypertension Center
Pulmonary, Critical Care and Sleep Division
Tufts Medical Center